[go: up one dir, main page]

CO2018006929A2 - "compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer" - Google Patents

"compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer"

Info

Publication number
CO2018006929A2
CO2018006929A2 CONC2018/0006929A CO2018006929A CO2018006929A2 CO 2018006929 A2 CO2018006929 A2 CO 2018006929A2 CO 2018006929 A CO2018006929 A CO 2018006929A CO 2018006929 A2 CO2018006929 A2 CO 2018006929A2
Authority
CO
Colombia
Prior art keywords
cancer
treatment
thiadiazole compounds
methoxy
hydrogen
Prior art date
Application number
CONC2018/0006929A
Other languages
English (en)
Inventor
Mark David Charles
Maurice Raymond Verschoyle Finlay
Johannes Wilhelmus Maria Nissink
James Matthew Wood
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of CO2018006929A2 publication Critical patent/CO2018006929A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPUESTOS DE 1,3,4-TIADIAZOL Y SU USO EN EL TRATAMIENTO DEL CÁNCER" Un compuesto de Fórmula (I): (I) o una sal farmacéuticamente aceptable del mismo, en la que: Q puede ser 5-metilpiridazin-3-ilo, 5-cloropiridazin-3-ilo, 6-metilpiridazin-3-ilo, o 6-fluoropiridazin-3-ilo; R puede ser hidrógeno, flúor, o metoxi; R1 puede ser hidrógeno, metoxi, difluorometoxi, o trifluorometoxi; y R2 puede ser metilo o etilo. El compuesto de fórmula (I) puede inhibir la glutaminasa, por ejemplo, GLS1.
CONC2018/0006929A 2015-11-30 2018-06-29 "compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer" CO2018006929A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260787P 2015-11-30 2015-11-30
PCT/EP2016/079251 WO2017093300A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
CO2018006929A2 true CO2018006929A2 (es) 2018-10-10

Family

ID=57421876

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0006929A CO2018006929A2 (es) 2015-11-30 2018-06-29 "compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer"

Country Status (25)

Country Link
US (1) US9938265B2 (es)
EP (1) EP3383871B1 (es)
JP (1) JP6873132B2 (es)
KR (1) KR20180083412A (es)
CN (1) CN108349967B (es)
AR (1) AR106876A1 (es)
AU (1) AU2016363719B2 (es)
BR (1) BR112018010812A2 (es)
CA (1) CA3005516C (es)
CL (1) CL2018001408A1 (es)
CO (1) CO2018006929A2 (es)
DK (1) DK3383871T3 (es)
DO (1) DOP2018000134A (es)
EA (1) EA201891240A1 (es)
ES (1) ES2759940T3 (es)
IL (1) IL258644A (es)
MX (1) MX2018006528A (es)
NI (1) NI201800065A (es)
PE (1) PE20181450A1 (es)
PH (1) PH12018501132A1 (es)
SG (1) SG11201803813UA (es)
SV (1) SV2018005701A (es)
TN (1) TN2018000126A1 (es)
TW (1) TW201730188A (es)
WO (1) WO2017093300A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10040789B2 (en) * 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
ES2939506T3 (es) * 2018-10-16 2023-04-24 Medshine Discovery Inc Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer
WO2025196446A1 (en) * 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU777824B2 (en) * 1999-11-24 2004-11-04 Merck Sharp & Dohme Corp. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1- piperazinepentanamides as HIV protease inhibitors
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
WO2006053342A2 (en) * 2004-11-12 2006-05-18 Osi Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
WO2010121918A1 (en) * 2009-04-20 2010-10-28 F. Hoffmann-La Roche Ag Proline derivatives as cathepsin inhibitors
HRP20192144T1 (hr) * 2011-11-21 2020-02-21 Calithera Biosciences Inc. Heterociklični inhibitori glutaminaze
LT2920168T (lt) * 2012-11-16 2021-10-25 Calithera Biosciences, Inc. Heterociklinis gliutaminazės inhibitorius
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
JP6666263B2 (ja) * 2014-01-06 2020-03-13 ライゼン・ファーマシューティカルズ・エスアー グルタミナーゼの新規阻害剤
WO2015138902A1 (en) * 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10040789B2 (en) 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
EA201891240A1 (ru) 2018-11-30
KR20180083412A (ko) 2018-07-20
JP6873132B2 (ja) 2021-05-19
DK3383871T3 (da) 2019-12-16
EP3383871A1 (en) 2018-10-10
MX2018006528A (es) 2019-05-15
PH12018501132A1 (en) 2019-01-21
CL2018001408A1 (es) 2018-10-12
AU2016363719A1 (en) 2018-07-05
PE20181450A1 (es) 2018-09-12
TW201730188A (zh) 2017-09-01
JP2019501134A (ja) 2019-01-17
AU2016363719A8 (en) 2018-07-12
EP3383871B1 (en) 2019-09-11
CN108349967A (zh) 2018-07-31
DOP2018000134A (es) 2018-06-30
ES2759940T8 (es) 2020-05-20
CA3005516C (en) 2024-04-16
US9938265B2 (en) 2018-04-10
WO2017093300A1 (en) 2017-06-08
CA3005516A1 (en) 2017-06-08
IL258644A (en) 2018-06-28
TN2018000126A1 (en) 2019-10-04
AR106876A1 (es) 2018-02-28
BR112018010812A2 (pt) 2018-11-27
SV2018005701A (es) 2018-11-27
US20170152254A1 (en) 2017-06-01
AU2016363719B2 (en) 2019-11-14
SG11201803813UA (en) 2018-06-28
CN108349967B (zh) 2022-02-15
NI201800065A (es) 2018-10-18
ES2759940T3 (es) 2020-05-12

Similar Documents

Publication Publication Date Title
CO2018006929A2 (es) "compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer"
GEP20237506B (en) Pcsk9 antagonist compounds
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
MX388748B (es) Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
MX376106B (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infección por virus de hepatitis b.
EA201791304A1 (ru) Производные изохинолина для лечения вич
MX2023000418A (es) Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia.
UA118149C2 (uk) Інгібітор jak
CL2018001407A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
CL2017001209A1 (es) Inhibidor de cinasa aurora a
AR103680A1 (es) Inhibidores selectivos de bace1
PE20170148A1 (es) Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer
AR112101A1 (es) Tinostamustina para usar en el tratamiento de la leucemia prolinfocítica de celulas t (t-pll).
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
CL2017002960A1 (es) Compuesto para la profilaxis o el tratamiento de daño al órgano
AR106849A1 (es) Compuestos de bis-piridazina y su uso en el tratamiento del cáncer
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
PH12017500487A1 (en) Use of heterocyclic fluoroalkenyl sulfone compounds for repelling molluscs
MX2018007796A (es) Compuestos de fenilimidazol.
AR111017A1 (es) Sal hemisulfato de un compuesto nucleotídico para el tratamiento del virus de la hepatitis c